Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

Structure

Volumn 23, Issue 12, 2015, Pages 2341-2348

  Zak, Krzysztof M ^a   Kitel, Radoslaw ^a   Przetocka, Sara ^a   Golik, Przemyslaw ^a   Guzik, Katarzyna ^a   Musielak, Bogdan ^a   Dömling, Alexander ^b   Dubin, Grzegorz ^a   Holak, Tad A ^a,c  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN PROGRAMMED DEATH 1; MEMBRANE PROTEIN; PROGRAMMED DEATH 1; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BINDING;

ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STOICHIOMETRY; AMINO ACID SEQUENCE; BINDING SITE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANTIGENS, CD274; BINDING SITES; HUMANS; MOLECULAR SEQUENCE DATA; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN BINDING;

EID: 84949228878     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2015.09.010     Document Type: Article

References (43)

1. P.D. Adams, P.V. Afonine, G. Bunkóczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, and et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. D Biol. Crystallogr. 66 2010 213 221
2. M. Ahmadzadeh, L.A. Johnson, B. Heemskerk, J.R. Wunderlich, M.E. Dudley, D.E. White, and S.A. Rosenberg Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood 114 2009 1537 1544
3. D.L. Barber, E.J. Wherry, D. Masopust, B. Zhu, J.P. Allison, A.H. Sharpe, G.J. Freeman, and R. Ahmed Restoring function in exhausted CD8 T cells during chronic viral infection Nature 439 2006 682 687
4. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, C.G. Drake, L.H. Camacho, J. Kauh, K. Odunsi, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 366 2012 2455 2465
5. D.S. Chen, and I. Mellman Oncology meets immunology: the cancer-immunity cycle Immunity 39 2013 1 10
6. Y. Chen, P. Liu, F. Gao, H. Cheng, J. Qi, and G.F. Gao A dimeric structure of PD-L1: functional units or evolutionary relics? Protein Cell 1 2010 153 160
7. X. Cheng, V. Veverka, A. Radhakrishnan, L.C. Waters, F.W. Muskett, S.H. Morgan, J. Huo, C. Yu, E.J. Evans, A.J. Leslie, and et al. Structure and interactions of the human programmed cell death 1 receptor J. Biol. Chem. 288 2013 11771 11785
8. A. Dömling, and T.A. Holak Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy Angew. Chem. Int. Ed. Engl. 53 2014 2286 2288
9. P. Emsley, B. Lohkamp, W.G. Scott, and K. Cowtan Features and development of Coot Acta Crystallogr. D Biol. Crystallogr. 66 2010 486 501
10. P.R. Evans Scaling and assessment of data quality Acta Crystallogr. D Biol. Crystallogr. 62 2006 72 82
11. G.J. Freeman Structures of PD-1 with its ligands: sideways and dancing cheek to cheek Proc. Natl. Acad. Sci. USA 105 2008 10275 10276
12. W.X. Guo, J.A. Wisniewski, and H. Ji Hot spot-based design of small-molecule inhibitors for protein-protein interactions Bioorg. Med. Chem. Lett. 24 2014 2546 2554
13. P.J. Hajduk, and J. Greer A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discov. 6 2007 211 219
14. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, R. Kefford, J.D. Wolchok, P. Hersey, R.W. Joseph, J.S. Weber, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med. 369 2013 134 144
15. E.A. Hawkes, A. Grigg, and G. Chong Programmed cell death-1 inhibition in lymphoma Lancet Oncol. 16 2015 234 235
16. R.S. Herbst, J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, J.A. Sosman, D.F. McDermott, J.D. Powderly, S.N. Gettinger, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
17. B.A. Inman PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression Cancer 109 2007 1499 1505
18. W. Kabsch XDS Acta Crystallogr. D Biol. Crystallogr. 66 2010 125 132
19. D. Koes, K. Khoury, Y. Huang, W. Wang, M. Bista, G.M. Popowicz, S. Wolf, T.A. Holak, A. Dömling, and C.J. Camacho Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists PLoS One 7 2012 e32839
20. M. Krug, M.S. Weiss, U. Heinemann, and U. Mueller XDSAPP: a graphical user interface for the convenient processing of diffraction data using XDS J. Appl. Crystallogr. 45 2012 568 572
21. E. Lázár-Molnár, Q. Yan, E. Cao, U. Ramagopal, S.G. Nathenson, and S.C. Almo Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2 Proc. Natl. Acad. Sci. USA 105 2008 10483 10488
22. D.Y. Lin, Y. Tanaka, M. Iwasaki, A.G. Gittis, H.P. Su, B. Mikami, T. Okazaki, T. Honjo, N. Minato, and D.N. Garboczi The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors Proc. Natl. Acad. Sci. USA 105 2008 3011 3016
23. E.J. Lipson, and C.G. Drake Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma Clin. Cancer Res. 17 2011 6958 6962
24. K.M. Mahoney, G.J. Freeman, and D.F. McDermott The Next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma Clin. Ther. 37 2015 764 782
25. J. Matsuzaki, S. Gnjatic, P. Mhawech-Fauceglia, A. Beck, A. Miller, T. Tsuji, C. Eppolito, F. Qian, S. Lele, P. Shrikant, and et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer Proc. Natl. Acad. Sci. USA 107 2010 7875 7880
26. A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, and R.J. Read Phaser crystallographic software J. Appl. Crystallogr. 40 2007 658 674
27. B.H. Moreno, and A. Ribas Anti-programmed cell death protein-1/ligand-1 therapy in different cancers Br. J. Cancer 112 2015 1421 1427
28. U. Mueller, R. Förster, M. Hellmig, F.U. Huschmann, A. Kastner, P. Malecki, S. Pühringer, M. Röwer, K. Sparta, M. Steffien, and et al. The macromolecular crystallography beamlines at BESSY II of the Helmholtz-Zentrum Berlin: current status and perspectives Eur. Phys. J. Plus 130 2015 141
29. S. Muenst, S.D. Soysal, F. Gao, E.C. Obermann, D. Oertli, and W.E. Gillanders The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer Breast Cancer Res. Treat. 139 2013 667 676
30. C.W. Murray, M.L. Verdonk, and D.C. Rees Experiences in fragment-based drug discovery Trends Pharmacol. Sci. 33 2012 224 232
31. G.N. Murshudov, P. Skubák, A.A. Lebedev, N.S. Pannu, R.A. Steiner, R.A. Nicholls, M.D. Winn, F. Long, and A.A. Vagin REFMAC5 for the refinement of macromolecular crystal structures Acta Crystallogr. D Biol. Crystallogr. 67 2011 355 367
32. T.G. Phan, G.V. Long, and R.A. Scolyer Multiple checkpoints on the long road towards cancer immunotherapy Immunol. Cell Biol. 93 2015 323 325
33. T. Powles, J.P. Eder, G.D. Fine, F.S. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H.A. Burris, D.P. Petrylak, S.L. Teng, and et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562
34. L.V. Riella, A.M. Paterson, A.H. Sharpe, and A. Chandraker Role of the PD-1 pathway in the immune response Am. J. Transplant. 12 2012 2575 2587
35. K. Sakuishi, L. Apetoh, J.M. Sullivan, B.R. Blazar, V.K. Kuchroo, and A.C. Anderson Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity J. Exp. Med. 207 2010 2187 2194
36. T.N. Schumacher, C. Kesmir, and M.M. van Buuren Biomarkers in cancer immunotherapy Cancer Cell 27 2015 12 14
37. J.C. Schwartz, X. Zhang, A.A. Fedorov, S.G. Nathenson, and S.C. Almo Structural basis for co-stimulation by the human CTLA-4/B7-2 complex Nature 410 2001 604 608
38. C.C. Stamper, Y. Zhang, J.F. Tobin, D.V. Erbe, S. Ikemizu, S.J. Davis, M.L. Stahl, J. Seehra, W.S. Somers, and L. Mosyak Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses Nature 410 2001 608 611
39. S. Sun, X. Fei, Y. Mao, X. Wang, D.H. Garfield, O. Huang, J. Wang, F. Yuan, L. Sun, Q. Yu, and et al. PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients Cancer Immunol. Immunother. 63 2014 395 406
40. S.L. Topalian, C.G. Drake, and D.M. Pardoll Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell 27 2015 450 461
41. P.C. Tumeh, C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, and et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 2014 568 571
42. E.J. Wherry T cell exhaustion Nat. Immunol. 12 2011 492 499
43. X. Zhang, J.C. Schwartz, X. Guo, S. Bhatia, E. Cao, M. Lorenz, M. Cammer, L. Chen, Z.Y. Zhang, M.A. Edidin, and et al. Structural and functional analysis of the costimulatory receptor programmed death-1 Immunity 20 2004 337 347